Measurement of renal function with new equation and clinical implications in multiple myeloma patients receiving lenalidomide

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003927

Enrollment

135

Registered

2015-05-12

Start date

2012-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90 N28

Interventions

Group 1: We have previously meticulously analyzed renal insufficiency (RI) in MM as well as specifically in patients receiving lenalidomide treatment. With substantially more patients at our instituti

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with multiple myeloma and presence of renal insufficiency and with therapy of Lenalidomide

Exclusion criteria

Exclusion criteria: Patients with multiple myeloma without therapy of Lenalidomide

Design outcomes

Primary

Measure	Time frame
Effectiveness of lenalidomide with respect . Improvement of renal insufficiency	—

Secondary

Measure	Time frame
Analysis of the specificity of two measurement methods of renal impairment.	—

Countries

Germany

Contacts

Public ContactMonika Engelhardt

Universitätsklinikum Freiburg

monika.engelhardt@uniklinik-freiburg.de+49 761 270 32460

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026